Literature DB >> 28754426

Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis.

S Stefani1, S Campana2, L Cariani3, V Carnovale4, C Colombo5, M M Lleo6, V D Iula7, L Minicucci8, P Morelli9, G Pizzamiglio10, G Taccetti2.   

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa is an important issue for physicians who take care of patients with cystic fibrosis (CF). Here, we review the latest research on how P. aeruginosa infection causes lung function to decline and how several factors contribute to the emergence of antibiotic resistance in P. aeruginosa strains and influence the course of the infection course. However, many aspects of the practical management of patients with CF infected with MDR P. aeruginosa are still to be established. Less is known about the exact role of susceptibility testing in clinical strategies for dealing with resistant infections, and there is an urgent need to find a tool to assist in choosing the best therapeutic strategy for MDR P. aeruginosa infection. One current perception is that the selection of antibiotic therapy according to antibiogram results is an important component of the decision-making process, but other patient factors, such as previous infection history and antibiotic courses, also need to be evaluated. On the basis of the known issues and the best current data on respiratory infections caused by MDR P. aeruginosa, this review provides practical suggestions to optimize the diagnostic and therapeutic management of patients with CF who are infected with these pathogens.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Antibiotic therapy; Antimicrobial susceptibility testing; Cystic fibrosis; Lung infection; Multidrug resistance

Mesh:

Substances:

Year:  2017        PMID: 28754426     DOI: 10.1016/j.ijmm.2017.07.004

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  26 in total

1.  Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.

Authors:  Hajira Bilal; Phillip J Bergen; Tae Hwan Kim; Seung Eun Chung; Anton Y Peleg; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

3.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

Review 4.  On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome.

Authors:  Bronwyn J E Lyons; Natalie C J Strynadka
Journal:  Medchemcomm       Date:  2019-06-20       Impact factor: 3.597

5.  Novel Aminoglycoside-Tolerant Phoenix Colony Variants of Pseudomonas aeruginosa.

Authors:  Devin Sindeldecker; Kelly Moore; Anthony Li; Daniel J Wozniak; Matthew Anderson; Devendra H Dusane; Paul Stoodley
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  High-throughput characterization of mutations in genes that drive clonal evolution using multiplex adaptome capture sequencing.

Authors:  Daniel E Deatherage; Jeffrey E Barrick
Journal:  Cell Syst       Date:  2021-09-17       Impact factor: 10.304

Review 7.  The Collaborative Cross mouse model for dissecting genetic susceptibility to infectious diseases.

Authors:  Hanifa Abu Toamih Atamni; Aysar Nashef; Fuad A Iraqi
Journal:  Mamm Genome       Date:  2018-08-24       Impact factor: 2.957

8.  Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.

Authors:  Hajira Bilal; Phillip J Bergen; Jessica R Tait; Steven C Wallis; Anton Y Peleg; Jason A Roberts; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 9.  Antibiofilm Peptides: Relevant Preclinical Animal Infection Models and Translational Potential.

Authors:  Gislaine G O S Silveira; Marcelo D T Torres; Camila F A Ribeiro; Beatriz T Meneguetti; Cristiano M E Carvalho; Cesar de la Fuente-Nunez; Octávio L Franco; Marlon H Cardoso
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-27

10.  Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa.

Authors:  Jonathan D Cogen; Frankline M Onchiri; Nicole Mayer Hamblett; Ronald L Gibson; Wayne J Morgan; Margaret Rosenfeld
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.